Oct 21, 2010 by Brian Orelli, PhDNice Earnings, Eli Lilly, but ...Cost cutting can only get you so far.
Oct 20, 2010 by Brian Orelli, PhDThere Are No Safe Biotech InvestmentsEven the sure-things sometimes aren't.
Oct 20, 2010 by Brian Orelli, PhDIntuitive Surgical: Time to Buy or Sleep Through the PainDown, but far from out.
Oct 20, 2010 by Brian Orelli, PhDWhat's Your Next Trick, Gilead?Nice sales growth, but it'll be tough to continue it.
Oct 19, 2010 by Brian Orelli, PhDWhy the FDA Won't Approve Lorcaserin and Qnexa (Yet)Obesity drugs get their day in front of the agency.
Oct 19, 2010 by Brian Orelli, PhDWhen the Status Quo Is a Big WinThe lack of an FDA rejection will do just fine.
Oct 18, 2010 by Brian Orelli, PhDPfizer Flexes Its Generic MusclesThe pharma giant moves farther into generic drugs.
Oct 13, 2010 by Brian Orelli, PhDThe King of Pharma Gets More RoyalPfizer snatches up King Pharmaceuticals.
Oct 13, 2010 by Brian Orelli, PhDDon't Get Addicted to Alkermes' Low RevenueOne FDA approval down, one more in the works.
Oct 12, 2010 by Brian Orelli, PhDClinical Trial Positive! Shares Just BarelyA story about expectations.
Oct 12, 2010 by Brian Orelli, PhDThese Drugmakers Are Still Friends After AllExelixis and Bristol-Myers are back together (still).
Oct 12, 2010 by Brian Orelli, PhDThis Drugmaker Stands on a Platform Above the RestImmunoGen signs up another partner.
Oct 11, 2010 by Brian Orelli, PhDWhat Meridia's Demise Means for Arena, VIVUS, and OrexigenSafety first ... and second ... and third.
Oct 11, 2010 by Brian Orelli, PhDA Dendreon Killer? Not Yet.Johnson & Johnson's abiraterone looks good, but won't knock off the newcomer.
Oct 11, 2010 by Brian Orelli, PhDFDA Rejection, but Still Jazzed UpSometimes, biotechs are like that.
Oct 8, 2010 by Brian Orelli, PhDPfizer's Rash (of Bad News) Is OverIts oral psoriasis drug, tasocitinib, works well.
Oct 8, 2010 by Brian Orelli, PhDIs Onyx Making Trouble?The FDA wants to know more about its drug manufacturing process.
Oct 7, 2010 by Brian Orelli, PhDAsset Sold, Questions BeginWhy did InterMune sells its stake in danoprevir?
